AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Pasithea Therapeutics Corp. Statistics
Share Statistics
Pasithea Therapeutics Corp. has 1.27M shares outstanding. The number of shares has increased by 21.56% in one year.
Shares Outstanding | 1.27M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 21.3% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.02M |
Failed to Deliver (FTD) Shares | 719 |
FTD / Avg. Volume | 1.67% |
Short Selling Information
The latest short interest is 11.58K, so 0.91% of the outstanding shares have been sold short.
Short Interest | 11.58K |
Short % of Shares Out | 0.91% |
Short % of Float | 1.13% |
Short Ratio (days to cover) | 0.32 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is -4.73.
PE Ratio | -0.59 |
Forward PE | -4.73 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 0.4 |
P/FCF Ratio | -0.73 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pasithea Therapeutics Corp..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.
Current Ratio | 6.34 |
Quick Ratio | 6.35 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0.35 |
Cash Flow / Debt | -164.37 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -68.05%.
Return on Equity (ROE) | -0.68% |
Return on Assets (ROA) | -0.61% |
Return on Capital (ROIC) | -68.05% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.00M |
Employee Count | 8 |
Asset Turnover | 0 |
Inventory Turnover | -16.01 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -65.52% in the last 52 weeks. The beta is 0.82, so Pasithea Therapeutics Corp.'s price volatility has been higher than the market average.
Beta | 0.82 |
52-Week Price Change | -65.52% |
50-Day Moving Average | 3.03 |
200-Day Moving Average | 4.94 |
Relative Strength Index (RSI) | 38.8 |
Average Volume (20 Days) | 43.12K |
Income Statement
Revenue | n/a |
Gross Profit | -648.45K |
Operating Income | -15.98M |
Net Income | -15.96M |
EBITDA | -15.33M |
EBIT | n/a |
Earnings Per Share (EPS) | -12.65 |
Balance Sheet
The company has 16.33M in cash and 81.68K in debt, giving a net cash position of 16.25M.
Cash & Cash Equivalents | 16.33M |
Total Debt | 81.68K |
Net Cash | 16.25M |
Retained Earnings | -35.32M |
Total Assets | 18.64M |
Working Capital | 9.12M |
Cash Flow
In the last 12 months, operating cash flow was -13.43M and capital expenditures -34.30K, giving a free cash flow of -12.85M.
Operating Cash Flow | -13.43M |
Capital Expenditures | -34.30K |
Free Cash Flow | -12.85M |
FCF Per Share | -10.18 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
KTTA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -506% |
FCF Yield | -405.82% |
Analyst Forecast
Currently there are no analyst rating for KTTA.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 2, 2024. It was a backward split with a ratio of 1:20.
Last Split Date | Jan 2, 2024 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -2.83 |
Piotroski F-Score | 4 |